trending Market Intelligence /marketintelligence/en/news-insights/trending/1qyczvvghmgkohgnwcytua2 content esgSubNav
In This List

Spring Bank Pharmaceuticals adds director to help develop hepatitis B drug

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Spring Bank Pharmaceuticals adds director to help develop hepatitis B drug

Hopkinton, Mass.-based Spring Bank Pharmaceuticals Inc. appointed Timothy Clackson as an independent member of its board.

Clackson was most recently president of research and development at Ariad Pharmaceuticals Inc., which was acquired by Takeda Pharmaceutical Co. Ltd.

Clackson's experience in biopharmaceutical development will help Spring Bank in the development of its hepatitis B treatment inarigivir, the company said in a news release.